NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Phase 2

Active, not recruiting

Conditions: Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Renal Cell Carcinoma
TFE3-Rearranged Renal Cell Carcinoma

Interventions: Drug: Axitinib
Biological: Nivolumab

First Posted Date: 2018-07-23

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT03595124

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 268 locations

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IIIB Colon Cancer AJCC v8
Stage IIIC Colon Cancer AJCC v8
Stage IVB Colon Cancer AJCC v8
Metastatic Rectal Adenocarcinoma
Stage III Colon Cancer AJCC v8
Stage IVA Colon Cancer AJCC v8
Stage IVC Colon Cancer AJCC v8
Stage IVC Rectal Cancer AJCC v8
Unresectable Rectal Adenocarcinoma
Stage IIIC Rectal Cancer AJCC v8

Interventions: Drug: Savolitinib

First Posted Date: 2018-07-19

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT03592641

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 30 locations

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Active, not recruiting

Conditions: Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Platinum-Resistant Ovarian Carcinoma
Ovarian High Grade Serous Adenocarcinoma

Interventions: Biological: Anetumab Ravtansine
Biological: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2018-07-16

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT03587311

Locations: 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 20 locations

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Phase 2

Active, not recruiting

Conditions: Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma

Interventions: Radiation: Radiation Therapy
Drug: Temozolomide
Drug: Veliparib

First Posted Date: 2018-07-10

Last Posted Date: 2025-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT03581292

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 160 locations

Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

Phase 2

Withdrawn

Conditions: Chronic Hepatitis B

Interventions: Biological: hepatitis B immune globulin (HBIg)
Drug: Pegylated interferon alfa (pegIFN)

First Posted Date: 2018-07-02

Last Posted Date: 2022-04-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT03575208

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Phase 1

Completed

Conditions: Carcinoma, Small Cell
Lung Cancer
Small Cell Lung Cancer

Interventions: Drug: M7824
Drug: Topotecan
Drug: Temozolomide
Diagnostic Test: EKG
Diagnostic Test: CT scan
Diagnostic Test: PET scan
Drug: Acetaminophen
Drug: Antihistamines
Drug: Diphenhydramine
Drug: Dexamethasone
Drug: Epinephrine

First Posted Date: 2018-06-13

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT03554473

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers

Not Applicable

Completed

Conditions: Glioblastomas
Sarcoma
Astrocytoma
Leukemia
Brain Cancer

Interventions: Behavioral: Psychoeducation
Behavioral: Enhanced Mindfulness Intervention

First Posted Date: 2018-05-29

Last Posted Date: 2023-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03538587

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Olaparib in People With Malignant Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

Interventions: Drug: Olaparib
Device: ClinOmics

First Posted Date: 2018-05-22

Last Posted Date: 2021-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT03531840

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Phase 2

Terminated

Conditions: Metastatic Castration Resistant Prostate Cancer
Prostate Neoplasms

Interventions: Drug: enzalutamide
Drug: CRLX101

First Posted Date: 2018-05-22

Last Posted Date: 2022-07-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT03531827

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

Not Applicable

Completed

Conditions: Neurofibroma, Plexiform
Neurofibromatosis 1

Interventions: Behavioral: Medication Event Monitoring System (MEMS^TM)
Other: Questionnaires

First Posted Date: 2018-05-22

Last Posted Date: 2024-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03531814

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy